CDT Equity Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $25.8K
- Price
- $0.836
- % Change (Daily % change from the live per-ticker quote feed.)
- -10.12%
- Volume
- 491.6K
About
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Quick stats
Shares outstanding30.8K
Computed float27.6K
Float / shares89.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001896212
Websitehttps://www.cdtequity.com
AI Summary
AI-generated1/31
minorbullishoperations update
CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
CDT Equity Inc. (Nasdaq: CDT) highlighted a new IP filing by Sarborg Limited applying quantum sampling to disease biology and drug discovery, covering 150 disease networks including Crohn's disease, COPD, and psoriasis.
CDT holds 1,290 shares in Sarborg, a 22.7% stake; Sarborg's latest raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 million.
Sarborg is in discussions with a leading global quantum computing company to run these models on quantum hardware, but the partnership is not yet signed and the announcement is largely promotional for CDT's stake value.
Red flags
- Valuation based on a private round at $125,000 per share with no public market for Sarborg shares; mark-to-market of CDT's stake is unverifiable
- Quantum computing partnership is only 'active discussions', not a signed agreement
- Release reads as promotional; no direct revenue or cash benefit to CDT disclosed
- Forward-looking statement boilerplate references Nasdaq listing-maintenance risk and a prior reverse stock split